AMG 193 + carboplatin + paclitaxel + pembrolizumab

This is a **combination regimen** of four agents: - **AMG 193**: a CNS-penetrant small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5), specifically designed to exploit synthetic lethality in MTAP-deleted tumor cells[1][2]. - **Carboplatin**: a platinum-based chemotherapy drug that induces DNA crosslinking and apoptosis in cancer cells. - **Paclitaxel**: a microtubule stabilizer chemotherapy agent that blocks cell division. - **Pembrolizumab**: a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing T-cell mediated anticancer immunity. This combination is currently under investigation for the treatment of **advanced MTAP-null solid tumors**, aiming to maximize antitumor activity by integrating targeted inhibition of PRMT5, cytotoxic chemotherapy, and immunotherapy[5][6]. AMG 193 has shown favorable safety and promising efficacy signals in early-phase clinical trials, particularly in patients with MTAP-deleted cancers[1][2][6].